DPx Holdings B.V. Reaches Definitive Agreement to Acquire Gallus BioPharmaceuticals

DURHAM, NC and ST. LOUIS, MO–(Marketwired – August 27, 2014) – DPx Holdings B.V., privately owned by JLL Partners and Royal DSM, is pleased to announce that it has reached a definitive agreement to acquire all shares of Gallus BioPharmaceuticals, LLC, a leading contract manufacturing company specializing in biologics and current portfolio company of Ridgemont Equity Partners. Following the transaction, Patheon’s biologic drug substance business, a unit of DPx Holdings, will span four facilities in Europe, Australia and North America and include 550 employees globally.

Source: http://www.marketwired.com/mw/release.do?id=1941714&sourceType=3